Abstracts tagged "COVID-19"

Abstract Number: 0007 • ACR Convergence 2020
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey
Emily Sirotich¹, Kevin Kennedy², Salman Surangiwala³, Teresa Semalulu¹, Maggie Larche¹, Jean Liew⁴, Zachary Wallace⁵, Philip Robinson⁶, Rebecca Grainger⁷, Jeffrey Sparks⁸, Julia Simard⁹, Jinoos Yazdany¹⁰, Monique Gore-Massy¹¹, Richard Howard¹², Mitchell Levine² and Jonathan Hausmann¹³, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴University of Washington, Seattle, WA, ⁵Massachusetts General Hospital, Newton, MA, ⁶University of Queensland, Herston, Queensland, Australia, ⁷University of Otago, Wellington, New Zealand, ⁸Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁹Stanford Medicine, Stanford, CA, ¹⁰UCSF, San Francisco, CA, ¹¹Lupus Foundation of America, Brooklyn, NY, ¹²Spondylitis Association of America, Van Nuys, CA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA
Background/Purpose: Early in the COVID-19 pandemic, hydroxychloroquine and chloroquine were empirically promoted and used for treatment and prevention of SARS-CoV-2 infection. The repurposing of these…
Abstract Number: 0051 • ACR Convergence 2020
COVID-Related Distress and Mental Health in Adult Rheumatology Patients During the COVID-19 Pandemic
Shereen Mahmood¹, Laura Curiel-Duran², Ruchika Darapaneni², Dalynah Maldonado², Lindsay Pattison², Emilee Tu² and Tamar Rubinstein³, ¹Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY, ²Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: The novel coronavirus disease 2019 (COVID-19) pandemic has significantly affected all aspects of society, especially in the epicenters of New York City (NYC) and…
Abstract Number: 0467 • ACR Convergence 2020
Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab
Cathy Melong Pianta¹, Kim Lauper¹, Delphine Courvoisier¹, Tim Cunningham², Daniéle Allali³ and Axel Finckh⁴, ¹Division of rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Private practice, Geneva, Geneva, Switzerland, ³Division of immunology, Geneva University Hospitals, Geneva, ⁴Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: The prevalence of anti-SARS-CoV-2 IgG infection was estimated at 9.7% in the Geneva population end of April 2020. (1) Immunosuppressed patients may be at…
Abstract Number: 0614 • ACR Convergence 2020
Impact of COVID-19 Pandemic on the Rheumatology Practice in Mexico: Mexican College of Rheumatology Survey
Natllely Ruiz¹, José Enrique Ruiz Guizar², Erick A Zamora Tehozol³, Iris Jazmín Colunga Pedraza⁴, Cristina Hernández-Díaz⁵, Vijaya Rivera-Terán⁶, Cesar Pacheco Tena⁷ and Deshire Alpizar-Rodriguez⁶, ¹Instituto Nacional de Enfermedades Respiratorias, Mexico City, Distrito Federal, Mexico, ²Independent, Mexico City, Distrito Federal, Mexico, ³Centro Médico Pensiones, Merida, Yucatan, Mexico, ⁴Rheumatology service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, ⁵Instituto Nacional de Rehabilitación, Mexico City, Distrito Federal, Mexico, ⁶Colegio Mexicano de Reumatología, Mexico City, Distrito Federal, Mexico, ⁷Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico
Background/Purpose: COVID-19 pandemic is an evident challenge for healthcare systems and daily clinical practice in developing countries. Particularly, chronic diseases attention has faced difficulties. The…
Abstract Number: 0984 • ACR Convergence 2020
Neighborhood Deprivation and Race/Ethnicity Affects COVID-19 Risk and Severity in SLE
Ashira Blazer¹, Ruth Fernandez-Ruiz², Mala Masson², Rebecca Haberman³, Rochelle Castillo⁴, Jose Scher⁴, Huda Algasas⁵, Allison Guttmann², Philip Carliucci³, Kristina Deonaraine², Michael Golpanian⁶, Kimberly Robins², Miao Chang², H. Michael Belmont⁶, Jill Buyon⁷, Amit Saxena³ and Peter Izmirly⁶, ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, ³NEW YORK UNIVERSITY SCHOOL OF MEDICINE, New York, NY, ⁴NYU School of Medicine, New York City, ⁵Columbia University, New York, NY, ⁶New York University, New York, NY, ⁷Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Disparities have been reported during the coronavirus disease (COVID-19) outbreak. Systemic lupus erythematosus (SLE) patients represent a unique group that is affected by clinical,…
Abstract Number: 1497 • ACR Convergence 2020
COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
Bonnie Bermas¹, Megan Clowse², Milena Gianfrancesco³, Jonathan Hausmann⁴, Pedro M Machado⁵, Emily Sirotich⁶, Helen Robinson⁷, Anja Strangfeld⁸, Jinoos Yazdany⁹ and Philip Robinson¹⁰, ¹UTSouthwestern.edu, Dallas, TX, ²Duke University, Chapel Hill, NC, ³University of California, San Francisco, San Francisco, CA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵University College London, London, United Kingdom, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Queensland School of Medicine, HERSTON, Queensland, Australia, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹UCSF, San Francisco, CA, ¹⁰University of Queensland, Herston, Queensland, Australia
Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…
Abstract Number: 0008 • ACR Convergence 2020
COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review
Akhil Sood¹, Arbi Galestanian¹, Vijaya Murthy², Emilio Gonzalez¹ and Mukaila Raji¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, League City, TX
Background/Purpose: Information about the outcomes of patients with rheumatic disease with SARS-CoV-2 infection is scarce. Patients with rheumatic disease on immunosuppressive medications might represent a…
Abstract Number: 0069 • ACR Convergence 2020
Identification of CD13 as a Potential Cause for SARS-CoV-2-triggered Hyperinflammation and Thrombosis
Eliza Pei-Suen Tsou¹, Gautam Sule¹, Mikel Gurrea Rubio², M. Asif Amin¹, Yu Zuo¹, Jason Knight¹, Yogendra Kanthi³ and David Fox¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³Division of Cardiovascular Medicine, Ann Arbor
Background/Purpose: The ectopeptidase CD13, which is highly expressed on stromal and myeloid cells in joints, lung and other tissues, is a known receptor for many…
Abstract Number: 0468 • ACR Convergence 2020
Concerns and Health-Related Behaviors During the COVID-19 Pandemic in Patients with or Without Autoimmune Rheumatic Disease in a Large Physician Network
Michael George¹, Shilpa Venkatachalam², Shubhasree Banerjee¹, Joshua Baker¹, Peter Merkel¹, David Curtis³, Kelly Gavigan⁴, Maria (Maio) Danila⁵, Daniel Kirby⁶, George Munoz⁷, William Sunshine⁸, William Nowell⁹ and Jeffrey R Curtis¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, ³Global Healthy Living Foundation, New York City, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵University of Alabama at Birmingham (UAB), Birmingham, AL, ⁶AARA, Charlotte, NC, ⁷AARA, Aventura, FL, ⁸AARA, Boca Raton, FL, ⁹Global Healthy Living Foundation, New York City, NY, ¹⁰Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with autoimmune rheumatic diseases (ARD) may be particularly concerned about COVID-19. We aimed to compare concerns and health-related behaviors of patients with common…
Abstract Number: 0623 • ACR Convergence 2020
Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort
Neha Chiruvolu¹, Muntarin Karim², Patil Injean³, Sandy Lee³, Karina Torralba⁴, Christina Downey³, Mehrnaz Hojjati⁵, Loomee Doo⁵, Donna Jose⁶, Deepa Panikkath³, Micah Yu⁵, Anna Lafian⁵, Marven Cabling⁵ and Vaneet Sandhu⁷, ¹UC Riverside School of Medicine, Riverside, CA, ²Loma Linda University Health System, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University School of Medicine, Redlands, CA, ⁵Loma Linda University Medical Center, Loma Linda, CA, ⁶Loma Linda University Medical Center, Ontario, CA, ⁷Loma Linda University, Loma Linda, CA
Background/Purpose: Cytokine Release Syndrome (CRS) or Macrophage Activation Syndrome (MAS) is a life threating hyperinflammatory condition that can complicate rheumatic disease as well as infections…
Abstract Number: 1140 • ACR Convergence 2020
How Did SARS-CoV2/COVID-19 Pandemic Affected Patients with Rheumatic Diseases in Latin America? A Regional Survey from PANLAR
Daniel Fernández-Ávila¹, Julián Barahona-Correa¹, Diana Romero-Alvernia¹, Sergio Kowalski², Ana María Sapag Durán³, Antonio Cachafeiro Vilar⁴, Belia Lucía Meléndez Muñoz⁵, Carlos Santiago Pastelín⁶, Claudia Ramírez⁷, Daniel Palleiro Rivero⁸, Diego Alejandro Jaimes⁹, Dina María Arrieta¹⁰, Guillermo Pons-Estel¹¹, Jossiell Then Báez¹², Manuel Ugarte-Gil¹³, Mario Cardiel¹⁴, Nelly Colman¹⁵, Nilmo Chávez Pérez¹⁶, Paula Burgos¹⁷, Rubén Montufar¹⁸, Sayonara Sandino¹⁹, Yurilis Fuentes-Silva²⁰ and Enrique Soriano²¹, ¹Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogota, Colombia, ²Unidad de Investigación PANLAR. Universidade Federal do Paraná, Paraná, Brazil, ³Hospital Universitario Japonés, Santa Cruz, Bolivia, ⁴Pacífica Salud - Hospital Punta Pacífica,, Ciudad de Panamá, Panama, ⁵Hospital de la Policía Nacional N1 Quito, Quito, Ecuador, ⁶Instituto Hondureño de la Seguridad Social, Tegucigalpa, Honduras, ⁷Organización Keralty, Bogota, ⁸Instituto Nacional de Reumatología del Uruguay - Universidad de la República, Montevideo, Uruguay, ⁹Clínicos IPS- Universidad de la Sabana, Bogotá D.C., Colombia, ¹⁰Hospital México, San José de Costa Rica, Costa Rica, ¹¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹²Hospital Metropolitano de Santiago (HOMS), Santiago, Dominican Republic, ¹³Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen and Universidad Científica del Sur, Lima, Peru, ¹⁴Centro de Investigación Clínica de Morelia, Morelia, Mexico, ¹⁵Hospital de Clínicas - Universidad Nacional de Asunción, Asunción, Paraguay, ¹⁶Instituto Guatemalteco de Seguridad Social, Ciudad de Guatemala, Guatemala, ¹⁷Universidad Católica de Chile, Santiago de Chile, Chile, ¹⁸Consultorio de Especialidades del Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador, ¹⁹Policlínica Nicaragüense, Managua, Nicaragua, ²⁰Centro Clínico Universitario de Oriente - Universidad de Oriente, Ciudad Bolivar, Venezuela, ²¹Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina
Background/Purpose: Social isolation during SARS-CoV-2/COVID-19 pandemic has undermined follow-up of patients with rheumatic diseases. These patients face a critical dilemma between the risk of exposure…
Abstract Number: 1576 • ACR Convergence 2020
Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review
Adam Kilian¹, Yu Pei Eugenia Chock², Irvin Huang³, Elizabeth Graef⁴, Laura Upton⁵, Aneka Khilnani⁶, Sonia Silinsky Krupnikova⁷, Ibrahim Almaghlouth⁸, Laura Cappelli⁹, Ruth Fernandez-Ruiz¹⁰, Brittany Frankel³, Jourdan Frankovich¹¹, Carly Harrison¹², Bharat Kumar¹³, Kanika Monga¹⁴, Jorge Rosario Vega¹¹, Namrata Singh¹⁵, Jeffrey Sparks¹⁶, Elaine Sullo⁶, Kristen Young¹⁷, Ali Duarte-Garcia¹⁸, Michael Putman¹⁹, Sindhu Johnson²⁰, Jean Liew³ and Aruni Jayatilleke²¹, ¹George Washington University, Washington, DC, ²Yale School of Medicine, Greenwich, CT, ³University of Washington, Seattle, WA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Georgetown University School of Medicine, Washington, DC, ⁶The George Washington University School of Medicine and Health Sciences, Washington, DC, ⁷The George Washington University School of Medicine and Health Sciences, Rockville, MD, ⁸King Saud University, Riyadh, Saudi Arabia, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰New York University School of Medicine, New York, ¹¹Temple University, Philadelphia, PA, ¹²Lupus Chat, NA, ¹³University of Iowa Hospitals and Clinics, Iowa City, IA, ¹⁴UT Health Rheumatology, HOUSTON, TX, ¹⁵University of Washington, Bellevue, WA, ¹⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁷University of Texas Southwestern Medical Center, Dallas, TX, ¹⁸Mayo Clinic, Rochester, MN, ¹⁹Northwestern University, Chicago, IL, ²⁰University of Toronto, Toronto, ON, Canada, ²¹Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Background/Purpose: COVID-19 threatens the health of people worldwide, although it remains unclear to what extent antirheumatic disease therapies increase susceptibility to complications of viral respiratory…
Abstract Number: 0009 • ACR Convergence 2020
Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases
Zakaria El Ouali¹, Elie Bassa¹, Abdoul-Rahamane Halidou Idrissa¹, Sarah Tazi¹, Samy Housbane², Mohamed Bennani Othmani², Kawtar Nassar¹ and Saadia Janani¹, ¹Department of Rheumatology, University Hospital of Ibn Rochd, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco, ²Medical Informatics Laboratory, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco
Background/Purpose: Antimalarial drugs (ADs), including chloroquine (CQ) and hydroxychloroquine (HCQ), have anti-inflammatory, immunomodulatory, antiparasitic, anti-thrombotic, and antiviral properties. Their indications in rheumatology have been known…
Abstract Number: 0079 • ACR Convergence 2020
Analysis of COVID-19 and Rheumatology Twitter Activity During the Pandemic Months
Mosaab Mohameden¹ and Ali H.Ali², ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²University of California San Francisco Fresno, Fresno, CA
Background/Purpose: Twitter is a popular social media platform that is widely used to publish information and exchange ideas. There are over 300 million active monthly…
Abstract Number: 0475 • ACR Convergence 2020
To Attend or Note to Attend; The Medical Student’s Dilemma
Benjamin Widener¹, Amy Cannella¹ and Sarah McBrien¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: We present a comparison of student’s outcomes with remote video-based learning versus lecture attendance in pre-clinical medical students during a musculoskeletal curriculum, thus allowing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].